PropThink: ArQule Reports 3Q Results as Investors Now Look to Tivantinib’s HCC Indication

[ACN Newswire] – By Jake KingOncology-focused ArQule, Inc. (NASDAQ:ARQL) reported third quarter financial results on Thursday morning, noting that cash, equivalents, and marketable investts totaled $140M on Sept. 30, and … more

View todays social media effects on ARQL

View the latest stocks trending across Twitter. Click to view dashboard